A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Hackensack Meridian Health
University of Chicago
Acerta Pharma BV
University of Maryland, Baltimore
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
University College, London
BeiGene
BeiGene
University of Rochester
City of Hope Medical Center
Mayo Clinic
University of Nebraska
TG Therapeutics, Inc.
Abramson Cancer Center at Penn Medicine
Brown University
Karyopharm Therapeutics Inc
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Cancer Research UK
ADC Therapeutics S.A.
Barbara Ann Karmanos Cancer Institute
Roswell Park Cancer Institute
Pharmacyclics LLC.
Dana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Mayo Clinic
Eli Lilly and Company
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
Pharmacyclics LLC.
Mayo Clinic
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Acrotech Biopharma Inc.
Fred Hutchinson Cancer Center
University of Arizona
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center